Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.

Published on IRCCS materno infantile Burlo Garofolo (https://www.burlo.trieste.it)

Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway. [1]

Titolo	Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway.
Publication Type	Journal Article
Authors	Zauli, G [2], Voltan, R [3], Bosco, R [4], Melloni, E [5], Marmiroli, S [6], Rigolin, GMatteo [7], Cuneo, A [8], Secchiero, P [9]
PubMed ID	21106726 [10]

Source URL: https://www.burlo.trieste.it/ricerca/pubblicazioni/dasatinib-plus-nutlin-3-shows-synergistic-antileukemic-activity-both-p53-wild-type-and-p53-mutated-b#comment-0

Collegamenti
[1] https://www.burlo.trieste.it/ricerca/pubblicazioni/dasatinib-plus-nutlin-3-shows-synergistic-antileukemic-activity-both-p53-wild-type-and-p53-mutated-b
[2] https://www.burlo.trieste.it/ricerca/biblio?f%5Bauthor%5D=104
[3] https://www.burlo.trieste.it/ricerca/biblio?f%5Bauthor%5D=224
[4] https://www.burlo.trieste.it/ricerca/biblio?f%5Bauthor%5D=222
[5] https://www.burlo.trieste.it/ricerca/biblio?f%5Bauthor%5D=269
[6] https://www.burlo.trieste.it/ricerca/biblio?f%5Bauthor%5D=993
[7] https://www.burlo.trieste.it/ricerca/biblio?f%5Bauthor%5D=994
[8] https://www.burlo.trieste.it/ricerca/biblio?f%5Bauthor%5D=995
[9] https://www.burlo.trieste.it/ricerca/biblio?f%5Bauthor%5D=98
[10] http://www.ncbi.nlm.nih.gov/pubmed/21106726?dopt=Abstract